Sanofi: quarterly EPS down by more than 7% at TCC
At nearly 10.5 billion euros, sales rose by 2.4% (+6.7% at CER), with growth 'driven by the continued strong performance of Dupixent and new launches', according to CEO Paul Hudson.
The French healthcare giant expects its 2024 business EPS to fall to the low single-digit range at CCT 'taking into account the expected increase in the tax rate, barring unforeseen major adverse events'.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction